NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, NEW ZEALAND, SINGAPORE, HONG KONG, THE REPUBLIC OF SOUTH AFRICA, OR JAPAN OR ANY OTHER JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.
This Announcement is not an admission document or a prospectus and should not be construed as an offer or form part of any offer to sell or issue, or solicitation of an offer to purchase or subscribe for, any of the securities mentioned in this Announcement nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. In particular, these materials are not an offer of securities for sale in the United States. Investors should not subscribe for or purchase any transferable securities referred to in this Announcement except on the basis of information in the Admission Document published on 11 June 2018.
14 June 2018
AQUIS EXCHANGE PLC
("Aquis" or the "Company")
Admission to AIM and First Day of Dealings
Aquis Exchange PLC, the independent, pan-European equities exchange operator and technology service provider, is pleased to announce that admission of its shares to trading on the AIM market of the London Stock Exchange will take place and dealings will commence at 8.00 a.m. today under the ticker AQX and the ISIN GB00BD5JNK30.
The Company's Admission Document can be found at http://www.aquis.eu/.
Aquis Exchange PLC
Alasdair Haynes, CEO
Jonathan Clelland, CFO and COO
Tel: +44 (0) 20 3597 6321
Liberum Capital Limited (Nominated Adviser and Broker)
Tel: +44 (0) 20 3100 2000
Finsbury (Financial Public Relations)
Tel: +44 (0) 20 7251 3801
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.